

Special Issue

Immunogenetic Regulations for Disease Prognosis

Message from the Guest Editors

Gaining insight into immunogenetic regulations is critical to further our understanding of the operation of the immune system at the molecular and cellular levels, devise personalized medicine strategies, and develop vaccines and therapies that are more efficacious against a wide range of immune-related ailments. This Special Issue features contributions to the field that enable in-depth research on drug effects and the mechanisms underlying disease progression, including advances in clinical biomarkers, regenerative medicine, microscopic techniques, heterologous gene expression, organ transplantation and multi-omics profiles. This Special Issue focuses on immune systems and their relationships to innovation, emerging technologies, natural medicine and the environment in order to present conceptual and practical advances regarding the state-of-the-art research on molecular and cellular mechanism. In order to create methods for early disease detection, real-time monitoring and prevention, it is intended to promote interest and research in this fascinating area.

Guest Editors

Dr. Anshuman Mishra

Translational Research & Sustainable Healthcare Management,
Institute of Advanced Materials, IAAM, 590 53 Ulrika, Sweden

Dr. Trim Lajqi

Department of Neonatology, Heidelberg University Children's Hospital,
Heidelberg, Germany

Deadline for manuscript submissions

30 September 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/195647

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).